Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
222 studies found for:    Open Studies | "Psoriasis"
Show Display Options
Rank Status Study
21 Unknown  TNF-alfa Inhibitors and Antibody Production in Patients With Psoriasis
Condition: Psoriasis
Intervention: Drug: subjects will receive either infliximab, adalimumab or etanercept
22 Unknown  The Impact of Targeted Therapy on Microorganism in Patients With Psoriasis
Condition: Psoriasis
23 Recruiting Haut-Tief Patient Education on Psoriasis and Eczema
Conditions: Psoriasis;   Atopic Dermatitis/ Eczema
Intervention: Behavioral: Control
24 Unknown  Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients
Conditions: Type 2 Diabetes;   Psoriasis
Intervention: Drug: GLP-1 analog
25 Unknown  The Effect of Alga Dunaliella Bardawil on Psoriasis
Condition: Psoriasis
Interventions: Dietary Supplement: Alga Dunaliella Bardawil placebo;   Dietary Supplement: Dunaliella Bardawil
26 Unknown  UVB-311nm After Initial Slow Response to Adalimumab in Psoriasis
Condition: Psoriasis
Interventions: Radiation: UVB-311nm;   Other: No treatment
27 Unknown  A Study of Topical Indigo Naturalis Treatment in Patients With Mild to Moderate Plaque-type Psoriasis
Condition: Psoriasis
Interventions: Drug: Indigo Naturalis;   Drug: Placebo
28 Recruiting Observational Study of Apremilast in Patients With Psoriasis in The Netherlands
Condition: Psoriasis
29 Not yet recruiting Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis
Condition: Psoriasis
Interventions: Drug: Metformin;   Drug: Placebo;   Drug: Topical Coal tar;   Drug: Topical calcipotriol
30 Not yet recruiting ASIS for Enbrel in Plaque Psoriasis
Condition: Plaque Psoriasis.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Enbrel subcutaneously at Week 12;   Drug: Efficacy of Enbrel subcutaneously at Week 24;   Drug: Efficacy of Enbrel subcutaneously at Week 36;   Drug: Efficacy of Enbrel subdermally at Week 12;   Drug: Efficacy of Enbrel subdermally at Week 24;   Drug: Efficacy of Enbrel subdermally at Week 36;   Drug: PASI 75 n(%) subcutaneously at Week 12;   Drug: PASI 75 n(%) subcutaneously at Week 24;   Drug: PASI 75 n(%) subcutaneously at Week 36;   Drug: PASI 75 n(%) subdermally at Week 12;   Drug: PASI 75 n(%) subdermally at Week 24;   Drug: PASI 75 n(%) subdermally at Week 36;   Drug: Adverse Reactions of Enbrel subcutaneously;   Drug: Adverse Reactions of Enbrel subdermally at Week 36
31 Unknown  The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis
Conditions: Psoriasis;   Cardiovascular Diseases;   Diabetes Mellitus, Type 2
Interventions: Drug: Adalimumab treatment arm;   Drug: Fumaric acid esters treatment group;   Other: Narrow band UVB radiation
32 Not yet recruiting Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
Condition: Psoriasis
Interventions: Drug: 0.5% Icotinib hydrochloride cream;   Drug: 1.0% Icotinib hydrochloride cream;   Drug: 2.0% Icotinib hydrochloride cream;   Drug: 4.0% Icotinib hydrochloride cream;   Drug: Placebo
33 Recruiting A Study of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions
Condition: Psoriasis
34 Recruiting A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Condition: Psoriasis
Interventions: Drug: GSK2894512 1% Cream;   Drug: GSK2894512 0.5% Cream;   Drug: Vehicle cream
35 Unknown  Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis
Conditions: Psoriasis;   Obesity;   Cardiovascular Risk;   Inflammation
36 Recruiting Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients
Condition: Psoriasis
Interventions: Drug: 1% icotinib hydrochloride cream;   Drug: 2% icotinib hydrochloride cream;   Drug: Placebo
37 Recruiting LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris
Condition: Psoriasis Vulgaris
Interventions: Drug: LEO 32731;   Drug: LEO 32731 Placebo
38 Unknown  Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis
Condition: Psoriasis
Intervention: Behavioral: Weight Loss
39 Recruiting Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis
Condition: Psoriasis
40 Recruiting An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Condition: Pustular Psoriasis
Intervention: Drug: Guselkumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years